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Background    The Guideline Working Group of the Korean Society for Neuro-Oncology (KSNO) 
conducted the nationwide questionnaire survey for diverse queries facing to treat patients with brain 
tumor. As part III of the survey, the aim of this study is to evaluate the national patterns of clinical prac-
tice for patients with brain metastasis and primary central nervous system lymphoma (PCNSL).
Methods    A web-based survey was sent to all members of the KSNO by email. The survey in-
cluded 7 questions of brain metastasis and 5 questions of PCNSL, focused on the management strat-
egies in specific situations. All questions were developed by consensus of the Guideline Working 
Group.
Results    In the survey about brain metastasis, respondents preferred surgical resection with 
adjuvant treatment for patients with a surgically accessible single brain metastatic lesion less than 3 
cm in size without extracranial systemic lesions. However, most respondents considered radiosurgery 
for surgically inaccessible lesions. As the preferred treatment of multiple brain metastases according to 
the number of brain lesions, respondents tended to choose radiotherapy with increasing number of le-
sions. Radiosurgery was mostly chosen for the brain metastases of less than or equal to 4. In the sur-
vey about PCNSL, a half of respondents choose high-dose methotrexate-based polychemotherapy as 
the first-line induction therapy for PCNSL. The consolidation and salvage therapy showed a little varia-
tion among respondents. For PCNSL patients with cerebrospinal fluid dissemination, intrathecal che-
motherapy was most preferred.
Conclusion    The survey demonstrates the prevailing clinical practice patterns for patients with 
brain metastasis and PCNSL among members of the KSNO. This information provides a point of refer-
ence for establishing a practical guideline in the management of brain metastasis and PCNSL.
Key Words  Korean Society for Neuro-Oncology; Practice patterns; Brain tumors; Metastasis; 
Lymphoma, Guideline Working Group.
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INTRODUCTION
The Guideline Working Group of Korean Society for Neu-
ro-Oncology (KSNO) conducted a nationwide questionnaire 
survey on the clinical practice about several topics of brain tu-
mor. The intent of this survey study is described in the previ-
ous article of the series in this issue. As part III of the survey, 
this study deals with practical decisions in the management of 
brain metastasis and primary central nervous system lympho-
ma (PCNSL). 
Brain metastases are the most common CNS tumors, with 
up to 30–40% of cancer patients developing brain metastases 
[1]. The management of brain metastases varies according to 
accessibility for surgical management, number of lesions, pa-
tients’ clinical status, and physicians’ preferences. According 
to National Comprehensive Cancer Network (NCCN) guide-
lines, surgery is recommended for a limited number of me-
tastases with lower level evidence (category 2A) [2], but no 
solid management guideline exists for extensive metastases or 
recurrent disease. A paucity of evidence and different clinical 
situations formed varied practice patterns across centers [3], 
and key questions for management strategies for brain metas-
tases include following: single metastasis with or without sur-
gical accessibility, disease status with or without systemic in-
volvement, and local or multiple recurrence after initial 
therapy.
PCNSL is a rare brain tumor and represents 3–4% of all brain 
tumors [4]. PCNSL is a highly aggressive non-Hodgkin lym-
phoma that is typically restricted to the brain, spine, cerebro-
spinal fluid (CSF), and eyes without evidence of systemic spread 
[5]. High-dose methotrexate (HD-MTX) plus consolidation 
chemotherapy and/or whole brain radiotherapy (WBRT) is the 
mainstay of standard of care for newly diagnosed PCNSL [6]. 
However, the optimal treatment regimen has yet to be defined. 
In addition, no consensus exists for refractory and relapsed 
PCNSL. Questions in this study deal with current controver-
sies including the optimal chemotherapy regimen, the role of 
radiation, the salvage management, and treatment of the CSF 
space [5].
The aim of this study is to evaluate the current status of 
clinical practice for patients with brain metastasis and PCNSL 
from the nationwide survey in Korea.
MATERIALS AND METHODS
The details of the study design, outline, and implementation 
are described in the previous article of the series in this issue. 
Here, the questionnaires about brain metastases (7 questions) 
and PCNSL (5 questions) were structured around existing 
controversies regarding real clinical management in patients 
(Appendix). 
Regarding to the brain metastasis, the survey questions 
dealt with the following specific situations related with the 
management plan of brain metastasis patient: 1) Single brain 
metastasis (initial management) depending on size; 2) Multi-
ple brain metastases (initial management) depending on 
symptom, location, and number of lesions; 3) Progressive sin-
gle brain metastasis with a failure of initial management; and 
4) Progressive multiple brain metastases.
 As for the PCNSL, the questionnaires were structured gen-
eral questions focused on the diagnostic work-ups and treat-
ment options. All responses were analyzed descriptively as 




The results of a survey on single brain metastasis manage-
ment options are shown in Fig. 1. For patients with a surgical-
ly accessible single brain metastatic lesion with size less than 3 
cm in diameter, 32 of 49 (65.3%) respondents preferred the 
surgical resection without (n=4) or with postoperative man-
agements such as, chemotherapy (n=2), WBRT (n=5), and ra-
diation boost to the surgical cavity (n=21). Seventeen (34.7%) 
respondents have chosen radiosurgery (n=16) and localized 
radiotherapy (n=1) without surgery as an initial treatment for 
the same lesion. However, if the patient has a surgically inac-
cessible single brain metastatic lesion less than 3 cm in diam-
eter without any other evidence of systemic disease, most re-
spondents (n=44, 89.8%) preferred the radiosurgery (including 
fractionated method) than localized radiotherapy (n=4, 8.2%) 
or WBRT (n=1, 2.0%).
For those patients with multiple brain metastases but if one 
of the lesions is showing mass effect and surgically accessible, 
most respondents (n=42, 85.7%) choose the surgical resection 
of the mass of interest followed by adjuvant treatment for the 
other lesions with radiosurgery in 8.2% (n=4), or radiothera-
py in 6.1% (n=3). There was similar tendency for choosing 
treatment modalities according to the number of lesions be-
tween conditions having extracranial metastases or not (Fig. 
2). Respondents considered the radiotherapy as the number 
of brain lesions increased, and the radiosurgery was mainly 
chosen at the brain metastases of less than or equal to 4. The 
consideration of chemotherapy combination increased when 
there were extracranial systemic lesions.
For enlarging single brain metastasis, which had been treat-
ed with radiosurgery or radiotherapy 3 months ago, respon-
dents considered the following options: short-term follow-up 
MRI within 1 or 2 months (n=31, 63.3%); decision-making 
after further work-up such as positron emission tomography 
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tic work-ups to identify the extent of PCNSL; brain MRI scan 
(including enhance, diffusion and perfusion images) (n=46, 
100%), ophthalmologic evaluation (n=38, 82.6%), whole-body 
PET scan (n=36, 78.3%), chest and/or abdominopelvic CT 
scan (n=32, 69.6%), spine MRI scan (if symptomatic) (n=31, 
67.4%), CSF analysis (n=31, 67.4%), brain CT scan (n=25, 
54.3%), bone marrow biopsy (n=17, 37.0%), testicular ultra-
sound for men >60 years (n=11, 23.9%), and serum LDH (n= 
1, 2.2%).
It was surprising to see that there is still a weak consensus 
on the initial management protocol for PCNSL. As a first-line 
induction therapy for PCNSL, 22 of 44 (50.0%) respondents 
considered HD-MTX-based polychemotherapy with (n=5) or 
without rituximab (n=17). Sixteen (36.4%) respondents used 
single-agent HD-MTX and six (13.6%) choose WBRT with or 
without chemotherapy. As the consolidation therapy for those 
(PET) and MR perfusion (n=7, 14.3%); surgical resection fol-
lowed by adjuvant treatment such as radiotherapy, radiosur-
gery, and chemotherapy (n=4, 8.2%); surgical resection only 
(n=4, 8.2%). Fig. 3 shows preference of respondents for the 
treatment strategies for patients with developing multiple 
brain metastases after treatment of single brain metastasis ac-
cording to previously treated modality. Localized radiotherapy 
or WBRT was the mainstay of the multiple metastases (n=36–
38, 78.3–84.4%), regardless the patients were treated with 
surgery, radiosurgery, or chemotherapy. When the patients had 
a history of radiotherapy, radiosurgery (n=22, 48.9%) was con-
sidered. Chemotherapy was preferred as combined therapy 
for radiosurgery, radiotherapy, and surgery.
PCNSL
Respondents were answered to consider following diagnos-
Fig. 1. Preferred management options in patients with small (diameter less than 3 cm) single brain metastasis without any evidence of systemic 
disease. WBRT, whole brain radiotherapy.
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Fig. 2. Treatment modality preference according to the number for multiple brain metastases brain lesions without extracranial systemic le-
sions or with extracranial systemic lesions.
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patients showing complete response after induction therapy, 
18 of 40 (42.5%) respondents choose high-dose WBRT at 45 
Gy (n=3) or low-dose WBRT at 23–24 Gy (n=15). One re-
spondent stated that the low-dose WBRT was given only to 
young patients. However, 19 of 40 (47.5%) respondents con-
sidered chemotherapy as the consolidation therapy. The regi-
mens were as followings: continuing HD-MTX based chemo-
therapy (n=12); high-dose chemotherapy with autologous stem 
cell transplantation (ASCT) (n=6); conventional chemothera-
py using cytarabine, etoposide plus cytarabine, or others (n=1). 
Three respondents (7.5%) choose the close observation with-
out consolidation therapy.
As the salvage therapy for patients showing partial response 
(PR), progressive disease (PD), and recurrence after induc-
tion therapy, 14 of 42 (33.3%) respondents choose the WBRT 
with (n=3) or without local boost (n=11). Sixteen (38.1%) re-
spondents choose the HD-MTX based chemotherapy and 
WBRT rechallenge and four (9.5%) respondents choose the 
single or combined chemotherapy using temozolomide, 
pemetrexed, topotecan, or rituximab. Four (9.5%) respondents 
considered ASCT and three (7.1%) considered the clinical trial. 
In free text response, one respondent stated that chemotherapy 
was performed for patients with PR or PD, and WBRT was 
performed for recurred patients. Fig. 4 shows the preferred 
management of respondents for PCNSL patients with CSF 
dissemination.
DISCUSSION 
The majority of practice patterns for single brain metastasis 
in Korea was consistent with the NCCN guideline. The main-
stay of management for accessible single metastasis was sur-
gery (65.3%) with or without adjuvant radiation at the surgical 
cavity, followed by radiosurgery (32.7%). This is in line with 
current evidence that the local control rate of brain metastases 
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Fig. 3. Treatment modality preference according to the previous treatment method for patients with developing multiple brain metastasis af-
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Fig. 4. Pie chart showing the management preference of respon-
dents for primary central nervous system lymphoma with cerebro-
spinal fluid dissemination.
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was comparable between radiosurgery and surgical resection 
group [7]. The preference options for the management for 
single brain metastasis was similar to those from international 
survey by radiation oncologists [3] who had chosen surgery 
and WBRT (40%), radiosurgery and WBRT (17%), and radio-
surgery alone (14%).
Interestingly, surgery was preferred (85.7%) for the symp-
tomatic lesion among the multiple metastases when it is sur-
gically accessible. This result is different from an international 
survey by radiation oncologists that 53% would not offer sur-
gery but give WBRT for multiple brain metastases [3]. The 
reason for that is the main respondents of our survey was neu-
rosurgeons (66.7%), followed by radiation oncologists (24.1%). 
Imaging findings after radiotherapy and radiosurgery can 
be confounded by treatment effects [8]. Physicians preferred 
to repeat scan with short-term interval of 1–2 month rather 
than additional advanced MRI or PET for enlarging single 
metastasis after radiosurgery or radiotherapy. When diag-
nosed with multiple recurrences, localized radiotherapy or 
WBRT was the most preferred treatment option, combination 
with chemotherapy.
PCNSL is usually present as a single brain lesion, but some-
times involves eyes, CSF, and rarely the spinal cord [9]. Thor-
ough clinical evaluation of PCNSL is mandatory to assess the 
extent of the disease and to treat patients. Practical guidelines 
from the NCCN and European Association for Neuro-Oncol-
ogy (EANO) commonly recommend ophthalmologic exam, 
CSF exam, spine MRI (if symptomatic), chest/abdominopel-
vic CT or whole-body PET/CT scan, bone marrow biopsy 
(lower level evidence), and testicular sonography (lower level 
evidence) [10]. The result of the survey in terms of clinical 
evaluation is generally in accordance with NCCN and EANO 
guidelines while both bone marrow biopsy and testicular so-
nography are performed less frequently.
In this survey, HD-MTX based chemotherapy with or with-
out other chemotherapeutic agents is revealed as a main strate-
gy for the induction therapy. In prospective studies, HD-MTX 
chemotherapy yielded a 52–100% response rate, while HD-
MTX-based polychemotherapy resulted in 65–100% response 
rate [6,11-13]. NCCN and EANO guidelines recommend that 
chemotherapy should include HD-MTX at doses of at least 
3g/m2 [10]. Interestingly, a minority of respondents use poly-
chemotherapy including rituximab, a monoclonal antibody 
directed against CD20 of the B-cell for CD20 positive PCNSL. 
The result of the IELSG32 phase 2 trial suggests that the com-
bination of HD-MTX, cytarabine, thiotepa, and rituximab 
(MATRix regimen) as the first-line treatment improves over-
all response rates [14]. To date, the level of evidence support-
ing the use of rituximab as part of protocol remains low, but 
several trials are ongoing to verify that addition of rituximab 
to induction therapy is beneficial [10].
Nearly half of clinicians choose the WBRT, especially low-
dose WBRT, as a main strategy for consolidation in this survey. 
In the largest and only phase 3 trial (G-PCNSL-SG 1) compar-
ing consolidation WBRT to observation alone, the overall sur-
vival was similar in patients underwent WBRT and those who 
did not [15]. In addition, high-dose WBRT negatively impacts 
on quality of life without the survival benefit in patients with 
PCNSL [16]. In accordance with the survey result, practical 
guidelines recommend reduced-dose consolidation radiother-
apy. Consolidation therapies based on continued HD-MTX 
chemotherapy, high-dose chemotherapy combined with ASCT, 
or other chemotherapeutic regimens are also revealed as pre-
ferred treatment options in practice.
Despite advances in first-line treatment, half of respondent 
relapse and a third of PCNSL patients have primary refracto-
ry disease [6]. The salvage regimen is poorly defined and var-
ied widely including HD-MTX rechallenge, temozolomide, 
topotecan, WBRT, rituximab, ASCT, and so on [17]. As the 
survey result for the salvage treatment, HD-MTX rechallenge 
or WBRT for those who have not received previously seems to 
be effective in retrospective studies [18,19]. For the CSF dis-
seminated disease, more than half of respondents choose in-
trathecal chemotherapy although no consensus exists regarding 
the role of intrathecal chemotherapy until now. Overall deci-
sion of salvage treatments should have been made based on 
patients’ situation and clinicians’ experiences.
As with any online survey, the major limitation of this study 
is response bias that respondents might be influenced by the 
pressure to follow the published guidelines, especially in the 
survey of PCNSL because of relatively few medical oncolo-
gists of the KSNO members. Additionally, the relatively low 
response rate may give rise to sampling bias interfering with 
the valuable interpretation of several questions. 
In conclusion, the survey demonstrates the variation and 
similarity of clinical practice for patients with brain metastasis 
and PCNSL among members of the KSNO. We could draw 
important issues to be studied for the establishment of guide-
lines based on the best available evidence.  
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Appendix
Brain metastasis 
1.  For patients with a surgically accessible single brain metastasis less than 3 cm in size without extracranial systemic lesions, what 
treatment would you recommend for patients? 
(      )  Surgical resection alone 
(      )  Surgical resection with postoperative radiation boost to the surgical cavity 
(      )  Surgical resection with postoperative whole brain radiotherapy 
(      )  Surgical resection with postoperative chemotherapy 
(      )  Radiosurgery alone 
(      )  Localized Radiotherapy alone 
(      )  Whole brain radiotherapy alone 
(      )  Chemotherapy alone
2.  For patients with a surgically inaccessible (e.g. brainstem) single brain metastasis less than 3 cm in size without extracranial 
systemic lesions, what treatment would you recommend for patients? 
(      )  Radiosurgery alone 
(      )  Localized radiotherapy alone 
(      )  Whole brain radiotherapy alone 
(      )  Chemotherapy alone
3.  For patients with one symptomatic surgically accessible brain metastatic lesion with mass effect and the other asymptomatic 
lesions without mass effect, do you recommend the surgical resection? 
(      )  Yes, I recommend surgical resection with postoperative further treatment. 
(      )  No, I recommend radiosurgery. 
(      )  No, I recommend radiotherapy. 
(      )  No, I recommend chemotherapy.
4.  For patients without extracranial systemic lesions, what treatment would you recommend for patients according to the number 
of brain metastatic lesions? (Choose all that apply)
a)  One lesion 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
b)  Two lesions 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
c)  Three lesions 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
d)  Four lesions 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
e)  Five to nine lesions 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
f)  Ten to nineteen lesions 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
g)  More than twenty lesions 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
5.  For patients with extracranial systemic lesions, what treatment would you recommend for patients according to the number of 
brain metastatic lesions? (Choose all that apply)
a)  One lesion 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
b)  Two lesions 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
c)  Three lesions 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
SK Kim et al.
27
d)  Four lesions 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
e)  Five to nine lesions 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
f)  Ten to nineteen lesions 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
g)  More than twenty lesions 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
6.  For patients with enlarging single brain metastasis on 3 months follow-up MRI after treatment radiosurgery or radiotherapy, 
what treatment would you recommend for patients? 
(      )  Short-term follow-up MRI check within 1 or 2 months 
(      )  Decision-making after further work-up such as PET and MR perfusion 
(      )  Repeat surgical resection alone 
(      )  Repeat surgical resection followed by adjuvant treatment 
(      )  Repeat radiosurgery or radiotherapy alone 
(      )  Other
7.  For patients with developing multiple brain metastases on 3 months follow-up MRI after treatment of single brain metastasis, 
what treatment would you recommend for patients according to previously treated modality? (Choose all that apply)
a)  Surgical resection only 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
b)  Radiosurgery only 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
c)  Radiotherapy only 
(      )   Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
d)  Chemotherapy only 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
e)  Surgical resection and radiosurgery 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
f)  Surgical resection and radiotherapy 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
g)  Surgical resection and chemotherapy 
(      )  Surgical resection   (      )  Radiosurgery   (      )  Radiotherapy   (      )  Chemotherapy
PCNSL
1.  What work-ups do you perform to identify the extent of PCNSL in your institution? (Choose all that apply) 
(      )  Brain CT scan 
(      )  Brain MRI scan (including enhance, diffusion and perfusion images) 
(      )  Spine MRI scan (if symptom exist) 
(      )  Ophthalmologic evaluation 
(      )  CSF analysis 
(      )  Whole-body PET scan 
(      )  Chest and/or abdominopelvic CT scan 
(      )  Bone marrow biopsy 
(      )  Testicular ultrasound for men >60 years 
(      )  Serum LDH 
(      )  Other
2.  What treatment do you recommend for first-line induction therapy of PCNSL in your institution? 
(      )  Whole-brain radiotherapy (WBRT) with or without chemotherapy 
(      )  Single-agent high dose methotrexate (HD-MTX) 
(      )  HD-MTX based polychemotherapy with cytarabine, ifosfamide or others 
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(      )  Rituximab and HD-MTX based polychemotherapy (R-MVP, R-MT, MATRix, R-MVBP, or others) 
(      )  Other
3.  What treatment do you recommend for consolidation therapy of PCNSL showing complete response after induction therapy in 
your institution? 
(      )  High-dose chemotherapy with autologous stem cell transplantation 
(      )  Conventional chemotherapy using cytarabine, etoposide plus cytarabine, or others 
(      )  Continue HD-MTX based chemotherapy 
(      )  High-dose WBRT (approximately 45 Gy) 
(      )  Low-dose WBRT (approximately 23–24 Gy) 
(      )  Observation 
(      )  Other
4.  What treatment do you recommend for salvage therapy of PCNSL showing partial response, progressive disease and recurrence 
after induction therapy in your institution? 
(      )  HD-MTX based chemotherapy and WBRT rechallenge 
(      )  Single or combined chemotherapeutic agents (e.g. temozolomide, pemetrexed, topotecan, or rituximab) 
(      )  Autologous stem cell transplantation 
(      )  Consider clinical trial 
(      )  WBRT alone 
(      )  Best supportive care 
(      )  Other
5.  What treatment do you recommend for PCNSL with CSF dissemination in your institution? 
(      )  Intrathecal chemotherapy 
(      )  Radiotherapy 
(      )  High-dose chemotherapy 
(      )  Best supportive care 
(      )  Other
